Seattle-based Icosavax, which is developing COVID-19 vaccines, files for IPO 4 years after launch
GeekWire
JULY 7, 2021
Icosavax creates virus-like particles with technology licensed from the University of Washington’s Institute for Protein Design. Icosavax filed a clinical trial application in Belgium in June for its RSV candidate and plans to initiate trials later this year, according to a company filing with the U.S. Icosavax Photo).
Let's personalize your content